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journal homepage: www.elsevier .com/locate /ajurRESEARCH HIGHLIGHTAcute kidney injury in China: A neglected truth
and perspectiveAcute kidney injury (AKI) affects approximately 13.3
million individuals and contributes to about 1.7 million
deaths globally per year. As estimated 85% of those
affected live in the developing world [1]. Although there
are various measures to prevent or treat AKI, including
renal protective drugs and continuous renal replacement
therapy, most of them have limited success or are still in
their infancy [2,3]. An additional study, newly published in
the Lancet, indicated that the number of people needing
renal replacement therapy is expected to be doubled,
from 2.62 million in 2010 to 5.44 million in 2030, with
spikes projected in Asia and Africa [4]. Therefore, AKI
remains a serious burden for the medical system, espe-
cially in developing countries. In 2013, the International
Society of Nephrology (ISN) launched a global target of
“0by25”, no patient deaths due to untreated acute kidney
failure by 2025, in order to improve the diagnosis and
treatment of AKI worldwide.
To reach this great aim, comprehensive information of
AKI in China is indispensable. China is the largest devel-
oping country in the world, and has not only vast territory,
but also different geological regions, coast and inland, and
56 races. In addition, huge differences existing in economic
status and heath care investment among these regions
affect the outcome of AKI. However, there is still lack of a
system database of AKI as the same in other developing
countries. Fortunately, Dr. Yang and colleagues [5]
launched a nationwide, cross-sectional survey of adult
hospitalized patients during JanuaryeJuly 2013 in mainland
China, evaluated the burden of AKI and assessed the
availability of diagnosis and treatment. This valuable study
timely published in Lancet, 2015 Oct 10.
The highlight of this study was including 22 out of 31
provinces, municipalities, and autonomous regions in
China, covering 82% population in the country, and four
geographical regions. The detection rate of AKI in over 200
million Chinese adults from 44 hospitals was near 1% ac-
cording to KDIGO criteria (the 2012 Kidney Disease:
Improving Global Outcomes) and 2% by the expanded
criteria (an increase or decrease in serum creatinine by 50%http://dx.doi.org/10.1016/j.ajur.2015.11.001
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tients was 12.4%, whereas 65% death rate was noticed in
the patients discharged with server AKI without further
treatment. The total deaths were about 0.7 million, so the
corrected mortality of recognized AKI should be just over
30% in this Chinese survey during 2013. The renal referral
was 21.4%, which was revealed as an independent protec-
tive factor for AKI mortality. Although the authors factually
discussion the limitations of this survey, it undoubtedly
provided a unique set of data for investigating the char-
acteristics of AKI, which also provided valuable guides for
formulating respective strategies in near future.
One of the shocking results from this study is the very
high non-recognition rate of AKI by the physicians in charge,
which is as high as 74.2% during hospital stay. Furthermore,
the rate of timely diagnosis of AKI is only 21.2%, while 4.6%
of AKI patients were diagnosed with delay, with no signifi-
cant difference between academic and local hospitals. The
data demonstrated that the medical doctors in China are
still lack of awareness of AKI in general. The slight increase
of serum creatinine is often ignored by doctors, which leads
to timely reexaminations also neglected. Physicians, espe-
cially renal specialists and intensive care unit specialists,
might pay more attention to renal function during hospital
stay, but surgeons might not evaluate renal function prop-
erly before surgery and follow-up in time after surgery.
However, there is lacking of data regarding the difference
of AKI recognition rate among different departments of the
hospitals in this study.
Another problem revealed was that only 16.7% of AKI
patients were reported to the health-care system (by ICD-
10 codes). This will result in remarkable underestimation of
the clinical and financial significance of AKI by the gov-
ernment/the medical authority, which could subsequently
influence the policy making, of course, the outcome of AKI
in 2025 as well. The significant regional difference of AKI
detection rate was also demonstrated by the authors. The
patients were more likely under-recognition of AKI in less
developed regions such as the southwest and the northwest
regions compared with more developed north China. Theon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
Research highlight 5divergent profile might be associated with environmental,
traditional and socioeconomic factors.
The additional alarming feature from this Chinese AKI
survey was the 71.6% high proportion of nephrotoxic drug
exposure before or at the time AKI developed, compared
with the 20%e50% reported in developed countries. The
authors discussed potential explanations, for instance, that
people can easily access a wide range of non-prescription
drugs including Western medicine and traditional Chinese
medicine. In China, many people like to take traditional
Chinese medicine in order to improve immune function
even without any disease, or help physical recovery post
operation. Some of them take daily traditional Chinese
medications as a routine for months without the instruction
from physicians, and subsequently suffered from renal
dysfunction. Apart from non-prescription medicines, peo-
ple could still access prescribed medicines, although the
prescription has been restricted. Inappropriately using
certain prescribed medicines will also cause AKI. The data
from this study should attract attention from the policy
makers in the government and the medical authority alike.
It is imperative to facilitate comprehensive education
and training programmes in China, to raise the awareness of
Chinese health-care authorities and professionals in severe
defects of AKI, to develop advanced methods for early
detection and treatment, to set up efficient and user-
friendly systems to identify and monitor AKI, including risk
assessment, response, renal support and rehabilitation, in
the hospitals over next 10 years, and to ultimately fulfil the
ISN initiative of 0by25 in China.
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